Weighing Engineered Grafts Against Established Transplant and Cell Therapy Approaches

Caspian Oliai, MD, MS, frames the choice among cell therapy products for acute leukemia around a single question: can the disease be cured by targeting one antigen, or does it require a more nonspecific but still robust immunotherapy. He uses B-cell acute lymphoblastic leukemia as an example, where a chimeric antigen receptor (CAR) T-cell therapy directed at one antigen may or may not be curative in a patient with high-risk features. That distinction separates autologous cell therapy from allogeneic approaches such as conventional stem cell transplantation, and for many high-risk diseases an allogeneic transplant remains necessary for cure, with one therapy sometimes serving as a bridge to the other. Emerging allogeneic off-the-shelf CAR T-cell and CAR natural killer cell products still rely on 1 or perhaps 2 antigens, so antigen escape and other relapse mechanisms mean a substantial share of patients with high-risk hematologic malignancies will continue to need a nonspecific allogeneic transplant. The key question, in his view, is how to engineer and fine-tune that transplant. He describes Orca-T as one strategy that addresses this directly by infusing defined cell types over several days: purified regulatory T cells reach solid organ sites before conventional T cells arrive, establishing an immune barrier that limits massive conventional T-cell proliferation and graft-vs-host disease while still permitting the activation needed for a graft-vs-leukemia effect and without increasing infection risk. Rawan Faramand, MD, agrees and adds that she is eager to see results from other graft engineering studies, including the SERENE-T trial in the reduced-intensity setting, given the aging population and the many patients ineligible for myeloablative conditioning. She also points to the Orca-Q trial and to the need for innovation for patients with mismatched unrelated or haploidentical donors, who were not included in Precision-T and who make up a growing share of the donor pool, particularly among ethnic minorities.